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Abstract
Introduction: We report on the adherence experience of a group of people living with HIV on ART over six years in
Uganda.
Methods: Between 2005 and 2009, we followed up 41 participants who were also part of a clinical trial comparing
home and facility based delivery of ART in Jinja, eastern Uganda. We conducted qualitative in-depth interviews at
enrolment, 3, 6, 18 and 30 months to capture experiences with adherence over time. In 2011 we returned to these
participants to find out how they were fairing with long term adherence. We managed to retrace 24 participants and
interviewed them about their experience. We thematically analysed the data and compared findings over time.
Results: Initially there were few barriers to adherence and many followed the adherence guidance closely. By year
six, relaxation of these rules was noticeable although self-reported adherence continued to be high. Alcohol
consumption was more common than before. Some relatives of the participants who had died claimed that some
deaths were a result of alcohol. While participants reported that ART had allowed them to reclaim independence and
return to work the changes in work and social routines created new challenges for adherence. Side effects like
lipodystrophy were not only causing some stigma but for some tested their faith in the drugs. Many participants
reported resumption of sexual lives but apart from those who selected same status partners, disclosure to new
partners was minimal.
Conclusion: Good adherence practice to ART wanes over the long-term, and people who may have disclosed at
initiation find it difficult to do so to new partners once they are healthy. Further adherence interventions and support
with disclosure over the course of therapy may need to be considered. (Words: 283)
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Introduction
About 25 million people are living with HIV-infection in Africa,
of whom approximately seven million are on antiretroviral
therapy [1]. Various studies, including systematic reviews, have
described the challenges of retaining patients on antiretroviral
therapy programmes but the evidence-base on adherence to
therapy remains weak [2-6]. As moves to roll-out `treatment as
prevention’ gather pace, there is an urgent need to understand
and address, barriers of access to care and adherence to
treatment. As Dieffenbach and Fauci [7] observed, major
barriers exist in many places and the effectiveness of
antiretroviral therapy will be compromised if those enrolled on
to treatment are not retained on care [8]. Good adherence is
not only essential to maintain patient health but also to prevent
the spread of resistance to antiretroviral therapy. A systematic
review published in 2006 suggested that adherence, measured
using quantitative indicators, was considerably better in Africa
than in the United States [9]. However, this seems implausible
since retention in care is poor and mortality rates among those
on antiretroviral therapy are considerably higher in Africa than
in developed countries [10]. Given the complexity of measuring
behaviour, further assessment of adherence is essential.
The meaning of being infected with HIV has changed for
patients over time from the certainty of imminent death and
dying during the earlier part of the epidemic [11,12] to more
recently of living with HIV as a chronic illness [12,13]. How this
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e78243
changed understanding of HIV-infection affects adherence to
antiretroviral therapy is not clear.
A number of studies have reported barriers to good
adherence to antiretroviral therapy in the initial period after
enrolment on to care, which have included: costs of visiting
clinics to access care [14], which can be as high as 10-20% of
monthly salary/wages per visit [15,16], occurrence of
unpleasant side effects, such as lipodystrophy [17-19] and HIV-
associated stigma [20,21].
Understanding of the challenges of adherence over time in
Africa remains largely unknown. We report the challenges to
adherence faced by patients after six years on antiretroviral
therapy in Jinja, Uganda.
Methods
The study participants were part of a 5-year cluster-
randomised trial conducted with The AIDS Support
Organisation (TASO) in Jinja, Uganda between 2005 and 2009.
The trial compared the effectiveness of two different delivery
models: home-based care with trained lay delivering drugs to
the home and providing adherence support versus providing
standard facility-based care [15]. The trial showed that both
strategies were approximately equally effective in terms of
virologic response and mortality. The home-based care
strategy was slightly cheaper for the health services and
markedly cost-saving for participants. Recruitment into the trial
began in 2005 and lasted for just under 2 years. Follow-up
continued until January 2009.
Nested within the trial was a social science study which
selected and followed 41 of the trial participants. These
participants were enrolled consecutively between October 2005
and April 2006 and stratified to ensure an equal number of
participants by gender, trial arm and clinical/immunological
stage [22]. Between the commencement of ART and the end of
the trial in 2009 seven of the 41 (17%) participants had died.
After 2009, the participants were reintegrated into the
delivery system of TASO which was a mixture of the facility,
home and community based models of ART delivery. The
facility-based model consisted of drug delivery at a designated
TASO clinic. The community model also referred to as
Community Drug Distribution Point (CDDP Model) involved
ART delivery at a distribution point in the community to ease
transport concerns of the people [23]. The distribution point
may be a church, school compound or a local health centre
within the community chosen by the participants. After initiation
onto ART in the facility based model, the participants were
evaluated clinically and psychosocially to determine their
readiness to move to the CDDP model, a period that usually
lasted between 3 to 6 months. Participants in the CDDP
received one to two monthly ART refills by a lay trained health
worker who was also charged with providing adherence
counselling and monitoring for side effects.
Between May and July 2011 we conducted follow up visits to
the participants in the qualitative study to find out about their
lives after the end of the trial. We attempted to revisit the 34
people who were last known to be alive in January 2009. One
of the interviewers who had been involved in the original
qualitative study carried out these follow up visits.
This research was approved by the Science and Ethics
Committee of The Uganda National Council of Science and
Technology, The Uganda National Council for Science and
Technology and the ethics committee of the London School of
Hygiene and Tropical Medicine. All participants provided
written informed consent.
Results
The interviewer traced and interviewed 24 (12 men and 12
women) out of the 34 participants. Of the other 10, six had died
sometime after the end of the trial and four had moved away
and could not be contacted. Only 4/24 (17%) people (all
women) reported not currently being in a relationship compared
to 29/41 (71%) at enrolment in 2005. The median age of
participants was now 46 (range 26 to 68) years. Only 4/24
(17%) people (all men) had acquired stable salaried
employment, while others had informal employment as
construction workers, petty traders, market vendors and
farmers. Overall, 6 of the 24 (25%) participants had had one or
more children since 2009. One man had three children born
from two partners. One woman was pregnant at the time of
interview in 2011, while another woman reported having
miscarried 2 times in the recent past.
The 6 participants who were reported to have died since
2009 comprised 4 men and 2 women. Relatives mentioned
alcohol-related problems in the case of the three men. The
other man and the two women were said to have died of
malaria (a term often used to mean a non-specific fever). Four
of the 6 who had died had reported to be adhering well to their
treatment in January 2009 when last interviewed at end of the
main trial.
In the next section we document the adherence experience
of the 24 people who were still alive.
Perceptions about Adherence Instructions
We found that most of the participants had become less
vigilant in managing their infection than they had been in 2009.
For example, some mentioned that they did not observe any
immediate consequences of not following the instructions they
had been given for their drug-taking regime when they began
ART 1 participant described one such incident:
I missed taking [ARV drugs] for three days. I had gone for a
burial and I had packed some drugs hoping to spend two or
three days but I found myself staying there for a week. At first I
thought that the rules were so strict and I was asking myself
how I could manage following them as I was a poor lady…Now
I am used to the drugs I don’t mind whether I eat something
first or not, I just take my drugs and I don’t have any problem
(Jane, aged 45)
Some of the instructions that they had been given as part of
the psycho-social readiness counselling before they started
taking drugs in 2005, included no smoking, no taking alcohol
and strict observance of time of drug taking. Most of the
participants told us that they were worried if the treatment was
taken beyond 30 minutes late. By 2011, some participants
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admitted that they were not following all the instructions given
and freely said this in interviews. One reported that joining
friends and sharing alcohol was in itself a testament of being
fully recovered, accepted and integrated into the community
without worrying about the potential consequences on
adherence:
… I tell you, we have a drinking place of malwa [Local beer]
but we share the local straws used for drinking that alcohol.
You know it is kept in one pot and we can gather more than six
people around that pot but we share the tube used to drink it. I
also take some alcohol, and I can find a friend in a bar and we
can share one bottle of beer. (Henry, aged 47)
Alcohol consumption was also mentioned as being partly to
blame for the deaths of some participants. We found in 2011
that consumption of alcohol was on the increase in this
population among both men and women, even when those
consuming it identified non consumption of alcohol as one of
the key rules that they should follow. Most of the men had
resumed the regular consumption of alcohol. One of the
participants (Ssebunya, aged 49) was reportedly taking so
much alcohol that it seemed to affect his livelihood and
sometimes TASO staff found it hard to trace him for his drug
supply. This is captured in the following observations by the
interviewer who had noticed physical changes in the
appearance of the participant:
Ssebunya had changed a lot, he had lost weight, he had
dark skin. His cheeks were swollen, his fingers were shaking
and his eyes were red as if he had had a sleepless night. As
soon as he entered the room, I smelt alcohol and whenever he
was talking I could smell alcohol, I suspected that he had drunk
some alcohol the night before. When he started selling
tomatoes and cabbages he got some money then he started to
take alcohol. He started drinking heavily. He has friends with
the same interests, they spend evenings in drinking places and
one day a counselor from TASO went searching for him and he
also found him in a drinking place. He took alcohol up to the
extent of spending nights in drinking places and he is also a
very keen smoker.
Work and Adherence
We had observed in 2009 after a median of 4 years since
ART initiation, that as their health had improved some
participants were taking up employment. By 2011 only 5 of 24
(21%) had relatively stable salaried jobs with one crediting ART
for allowing him to `stabilize’, return to school and secure well-
paid work. However the majority kept complaining about
poverty and an inability to earn a secure income while
managing the demands of adherence. Some admitted to
swallowing antiretroviral drugs without food, as mentioned
above, because they could not eat while working. Many of the
other participants reported that they were struggling to juggle
new work routines with proper adherence.
There are times when I miss the time. As I have told you that
sometimes we spend nights on the lake [fishing], when we
come back on the lake shore in the morning, we take breakfast
and go to sleep and for me my usual time of taking my drugs is
9.00 am and same time [9.00pm] in the evening. By that time I
might be asleep and by the time I wake up it is already past my
normal time…I can miss three times in a week. (Ssebunya,
aged 49)
Another participant who had been receiving drugs near the
lake shore close to her business was affected when the
decision was made to shift drug distribution to another point.
The change affected the smooth running of her work because
of the new location being more distant and she could not
always afford the transport to get her drugs:
I was getting my drugs from home and that was so easy for
me. Now I have to walk to the distribution centre and at times I
leave my fish out [to dry] and the wild birds eat it because I am
not around. We spend a whole day there and when I try to
leave my fish inside the house, it gets spoilt. (Mary, aged 34)
Continuing side effects
The side-effects of drugs, or worries about the potential side-
effects in the future were still a concern to many. Some
participants reported fat loss with sunken features around the
face, a characteristic of lipodystrophy: six of the 24 (25%)
participants, (three women and three men), expressed
considerable discomfort about their appearance. One woman
complained that her skin had darkened; two men and a woman
mentioned that their finger and toe nails had become visibly
dark and brittle.
Drug-regimes were reported to have been changed in
response to some of these side-effects, but for some the side-
effects persisted and those affected had become resigned to
the change in their appearance. A few of the affected people
were beginning to question the effectiveness of ART:
They told us that if you take these drugs, you don’t get other
sicknesses but now you see how my eye looks like, I hoped
that if I take the drugs for a long time all the sicknesses would
go and I remain with only the virus (Mary aged 34).
However, others who had deformities because of ART or
other visible signs which they had attributed to ART were
beginning to feel uncomfortable with the way they looked. They
had hoped that after 6 years on ART all would be well but the
persistence of these signs brought about feeling of worry that
gains were being reversed. Michael (aged 36) observed:
…You see it has changed its shape [referring to the shape of
mouth] and even my face is pale with sunken eyes. Even
though I try to add some jelly on my face it doesn’t change.
People can think that I don’t bathe properly according to the
way my skin looks. As a human being, I feel bad but there is
nothing to do about it.
Another female participant who was struggling with the side
effects also seemed to have less confidence in the
effectiveness of ART:
I can’t say that they have worked well because as you see
now my face it has changed from its normal shape, I don’t
know whether it is a type of drug or it is because I have spent
some time on them. I take Septrin and Efaviren. (Agatha, aged
47)
Experience with missed doses
Although few participants reported missing drugs (only three
admitted to this), the good adherence planning reported during
the 2005-2009 trial period had lapsed with drug taking
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becoming more erratic. However, almost all of participants
reported that while they did not take their drugs `on time’, they
only delayed swallowing drugs occasionally with some
regularly going beyond the one hour limit that many suggested
was allowable. It appeared that perceptions were shifting from
strict time keeping to merely swallowing tablets. A case in point
is participant Jane (aged 45) who commented that she would
sometimes miss her drugs for a number of days and even
when she took them, she was not always sure of the time:
…I don’t have an answer […] I just find myself missing time. I
just estimate it as I don’t have a watch and a radio in my home.
I used to know the time from the neighbour’s radio but we got
misunderstandings and I no longer go to their home.
Barriers to adherence did not only originate from the
participants’ side, in one case, a participant blamed the
provider:
I am no longer getting my medicine refills from the centre. I
get them from the distribution point which is near here at the
health centre. There was one day when they brought for me
the type of drugs which I was not taking before. The nurse told
me that the field officer was going to bring me the usual type of
drugs on the next day. I waited for the whole day and I didn’t
see the field officer. On the next day, I decided to go to the
centre to pick my drugs. I missed one full day and one extra
morning dose. (Angela aged 54)
HIV status disclosure after initiating ART
While most of the men and women said that they were
comfortable disclosing their HIV status to family members,
friends and workmates, as well as potential sexual partners,
others felt that telling people about their status was now
unnecessary. Some felt that they needed to be careful to keep
their status a secret to avoid discrimination at work. Some
feared that the negative public attitude may affect their
livelihood:
You know if people know your HIV status, they can abandon
your kiosk, now I am dealing in fresh foods, some people can
stop buying them. Some people are still ignorant, one can think
that if a person with HIV touches a mango the virus can be
spread to him or her (Michael aged 36)
There seemed to be little motivation to continue disclosing to
new people who had never known that they were HIV-positive.
Jonathan (aged 67) felt that it was not necessary for him to
disclose his status any more, given that he looked healthy.
However his desire for secrecy was causing him some
problems because the dosage time he had been given was not
working for him, due to work commitments, and he was in the
process of asking the counsellor to change it. He was
struggling to adhere to his drugs:
There is no reason why I should inform them [new people
including employer], they are not going to help me in anything.
Lucky enough my wife knows and she is the one looking after
me.
Experiences with sexual relationships
Attitudes to sex and pregnancy had already begun to change
in 2009, when the main study ended. This change had
persisted with most of those who had vowed to abstain from
sex when they had begun ART actively engaged in sex with
new partners. Disclosure to such partners was proving to be a
challenge. Of the 10 participants who had got new partners,
five were unsure of their partner’s status. These 5 had not
disclosed their own status to that new partner.
Seven of these10 participants reported having had a child or
a pregnancy in the last three years. Some did know their new
partners status:
”I found myself having resumed sex issues again. I never
expected to look like how I am now. I never expected to get a
sexual partner…We met at our treatment place and we got
attracted to each other….We both have the disease [HIV/AIDS]
and we had agreed on using condoms. I don’t know what
happened to my friend, only to find myself pregnant. She
(baby) is eight months old….For me I never liked to get a child
but I just saw that I was pregnant and you never know I might
say that I will not get a second child and I find myself getting
one”. (Matilda, aged 40)
Having new sexual partners potentially posed questions for
the participant because it involved worrying about the
pregnancy outcome and perhaps the need to change drugs at
some point because of changes brought by pregnancy.
There appeared to be a preference for partners who were
also HIV-positive. Sero-sorting it was argued allowed them to
avoid worrying about infecting someone else. The new partner,
who would be taking drugs themselves, would help with proper
adherence:
I no longer want to infect others, and a person who is also
HIV positive knows [the knowledge of what HIV positive people
experience] how they are expected to behave like using
condoms and drug taking. (William, aged 45)
Discussion
Our findings show that the incorporation of an HIV identity
does not follow a linear process as has been suggested [24].
Joining a support organisation has been documented as a
turning point [25] with the expectation that such organisations
do provide adequate support to PLHIV. Our study population
was part of The AIDS Support Organisation which has
historically emphasised positive living including the public
embrace of status through the time tested positive living
approaches [26]. Almost all TASO clients are given counselling
support to disclose their HIV status and disclosure rates at the
time of ART initiation were close to 100% in this population.
The importance of adherence was well understood by our
study participants and they managed to follow the ‘strict’
instructions in the first few years after initiating ART aided by
the strong psychosocial support system [27,28]. Such efforts
may have contributed to the high adherence rates that have
been reported in much of Sub-Saharan Africa [10]. However
with improvements in health comes multiple and sometimes
unanticipated adherence challenges. For example our
participants who had resumed sexual relationships often failed
to disclose their HIV sero status to new sexual partners as a
strategy to secure a stable source of livelihood, especially the
women. Such relationships inevitably led to pregnancies/child
birth and the non-disclosure presented challenges for proper
Adherence to Antiretroviral Therapy in Uganda
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adherence. It has already been documented that PLHIV tend to
reclaim sexual and reproductive lives after starting ART [29,30]
and that pregnant women are particularly vulnerable to poor
adherence especially in the first three months; a challenge our
participants would relate to [31]. Non-disclosure especially to
close companions like sexual partners has been associated
with poor adherence [2,9]. Our finding, that HIV disclosure
becomes a challenge some years after ART initiation, suggests
that people on ART may need continued follow-up support to
disclose their status to new partners, similar to the support
provided when ART is initiated.
It is worth noting the relaxation of the rules of adherence
from the time of the initiation of ART. At the start of treatment,
all our participants had vowed strictly to adhere to instructions
which included: no smoking, no alcohol, reduction in number of
partners and having food available to take with the drugs [27].
This was no longer the case five years later. Probably most
concerning was that alcohol consumption was reported to be
high for some and yet it is associated strongly with poor
adherence [32]. Our findings also demonstrate the difficulty in
managing an HIV identity in the context of a suspicious and
stigmatizing community. Some participants opted to hide their
status in the work context fearing that public knowledge could
lead to loss of income. Similar reactions about the challenges
of taking ART and building a life with HIV have been identified
in other settings [33]. Others had developed side effects which
were causing some discomfort and reduction in the faith in
medication they had built over the years. Adherence messages
may need to be enforced periodically, particularly in relation to
the avoidance of alcohol consumption and safer sex and that
given the persistence of side effects, regimens with poor
toxicity profiles, such as stavudine, should be completely
phased out. Some of our study population reported having
regimens substituted but there were no reports of failed
therapy. It is important to note that our study population were
clients of an NGO which believes strongly in support,
counselling and empowerment of patients and at the time of
ART initiation, these clients are likely to have been among the
most knowledgeable about ART and the need to adhere in
Africa. The need for regular periodic intervention to sustain
high levels of adherence in patients over the long term is likely
to be higher in other populations.
Conclusion
These findings highlight a number of issues that affect
adherence and potentially affect long-term survival outcomes.
While ART opens new social and economic opportunities, after
regaining better health, PLHIV have to think about fitting in
without compromising individual identities and values. Long
term adherence interventions that focus on unique individual
situations should be considered. These might include: regularly
re-engaging with PLHIV to understand and react to changing
contexts, re-emphasising the rules of adherence by focusing on
specific individual needs and challenging any complacency that
might grow into poor adherence. Larger studies among long
term users of ART might offer greater insight into the long term
challenges and opportunities among populations such as ours.
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